View Past PerformanceCytophage Technologies 대차대조표 건전성재무 건전성 기준 점검 6/6Cytophage Technologies 의 총 주주 지분은 CA$2.1M 이고 총 부채는 CA$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 CA$4.1M 및 CA$2.0M 입니다.핵심 정보0%부채/자본 비율CA$0부채이자보상배율n/a현금CA$1.24m자본CA$2.13m총부채CA$1.97m총자산CA$4.10m최근 재무 건전성 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.공시 • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.공시 • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.공시 • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.공시 • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.공시 • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.재무 상태 분석단기부채: CPTC.F 의 단기 자산 ( CA$1.4M )이 단기 부채( CA$768.4K ).장기 부채: CPTC.F의 단기 자산(CA$1.4M)이 장기 부채(CA$1.2M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: CPTC.F 부채가 없습니다.부채 감소: CPTC.F는 5년 전에 부채가 없었습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: CPTC.F 은 마지막 보고 무료 현금 흐름을 기준으로 4 개월 동안 충분한 현금 활주로를 보유하고 있지만 이후 추가 자본을 조달했다.예측 현금 활주로: CPTC.F 은 잉여현금흐름추정을 기준으로 4 개월 동안 충분한 현금 활주로를 확보할 것으로 예상되지만 이후 추가 자본을 조달했습니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/10/18 11:46종가2025/07/21 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cytophage Technologies Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.
공시 • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.
공시 • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.
공시 • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.
공시 • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.
공시 • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.